ID   OV-2295
AC   CVCL_9T13
SY   OV2295
DR   cancercelllines; CVCL_9T13
DR   GEO; GSM2474983
DR   Wikidata; Q54936823
RX   PubMed=22931248;
RX   PubMed=28273451;
CC   Doubling time: 2.90 +- 0.10 days (PubMed=22931248).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ile195Thr (c.584T>C); ClinVar=VCV000216077; Zygosity=Unspecified (PubMed=22931248; PubMed=28273451).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Miscellaneous: STR profile from personal communication of Mes-Masson, Anne-Marie.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 13
ST   D16S539: 12
ST   D21S11: 30
ST   D5S818: 13
ST   D7S820: 11,12
ST   TH01: 6
ST   TPOX: 11
ST   vWA: 14,15
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_9T14 ! OV-2295(R2)
OI   CVCL_9T18 ! TOV-2295(R)
SX   Female
AG   59Y
CA   Cancer cell line
DT   Created: 23-02-16; Last updated: 19-12-24; Version: 13
//
RX   PubMed=22931248; DOI=10.1186/1471-2407-12-379; PMCID=PMC3532154;
RA   Letourneau I.J., Quinn M.C.J., Wang L.-L., Portelance L., Caceres K.Y.,
RA   Cyr L., Delvoye N., Meunier L., de Ladurantaye M., Shen Z.,
RA   Arcand S.L., Tonin P.N., Provencher D.M., Mes-Masson A.-M.;
RT   "Derivation and characterization of matched cell lines from primary
RT   and recurrent serous ovarian cancer.";
RL   BMC Cancer 12:379.1-379.16(2012).
//
RX   PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028;
RA   Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J.,
RA   Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A.,
RA   Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J.,
RA   Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.;
RT   "Interrogation of functional cell-surface markers identifies CD151
RT   dependency in high-grade serous ovarian cancer.";
RL   Cell Rep. 18:2343-2358(2017).
//